RU2017145308A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017145308A3 RU2017145308A3 RU2017145308A RU2017145308A RU2017145308A3 RU 2017145308 A3 RU2017145308 A3 RU 2017145308A3 RU 2017145308 A RU2017145308 A RU 2017145308A RU 2017145308 A RU2017145308 A RU 2017145308A RU 2017145308 A3 RU2017145308 A3 RU 2017145308A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502055P | 2011-06-28 | 2011-06-28 | |
| US61/502,055 | 2011-06-28 | ||
| US201161570394P | 2011-12-14 | 2011-12-14 | |
| US61/570,394 | 2011-12-14 | ||
| US201161577204P | 2011-12-19 | 2011-12-19 | |
| US61/577,204 | 2011-12-19 | ||
| US201261638168P | 2012-04-25 | 2012-04-25 | |
| US61/638,168 | 2012-04-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014102583A Division RU2642310C2 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121797A Division RU2727452C1 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
| RU2019121798A Division RU2728861C1 (ru) | 2011-06-28 | 2019-07-11 | Слитые серпиновые полипептиды и способы их применения |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017145308A RU2017145308A (ru) | 2019-02-18 |
| RU2017145308A3 true RU2017145308A3 (pl) | 2019-02-18 |
| RU2698655C2 RU2698655C2 (ru) | 2019-08-28 |
Family
ID=47424806
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121797A RU2727452C1 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
| RU2017145308A RU2698655C2 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
| RU2014102583A RU2642310C2 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
| RU2019121798A RU2728861C1 (ru) | 2011-06-28 | 2019-07-11 | Слитые серпиновые полипептиды и способы их применения |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121797A RU2727452C1 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014102583A RU2642310C2 (ru) | 2011-06-28 | 2012-06-28 | Слитые серпиновые полипептиды и способы их применения |
| RU2019121798A RU2728861C1 (ru) | 2011-06-28 | 2019-07-11 | Слитые серпиновые полипептиды и способы их применения |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US8980266B2 (pl) |
| EP (2) | EP2726092B1 (pl) |
| JP (5) | JP2014523900A (pl) |
| KR (6) | KR20250012200A (pl) |
| CN (3) | CN110551223A (pl) |
| AU (4) | AU2012275287B2 (pl) |
| BR (1) | BR112013033799A2 (pl) |
| CA (2) | CA2839619C (pl) |
| CY (1) | CY1122195T1 (pl) |
| DK (1) | DK2726092T3 (pl) |
| ES (1) | ES2746052T3 (pl) |
| HR (1) | HRP20191652T1 (pl) |
| HU (1) | HUE046156T2 (pl) |
| IL (3) | IL312872A (pl) |
| IN (1) | IN2013MN02441A (pl) |
| LT (1) | LT2726092T (pl) |
| ME (1) | ME03473B (pl) |
| MX (2) | MX381183B (pl) |
| NZ (1) | NZ744257A (pl) |
| PL (1) | PL2726092T3 (pl) |
| PT (1) | PT2726092T (pl) |
| RS (1) | RS59368B1 (pl) |
| RU (4) | RU2727452C1 (pl) |
| SG (2) | SG10201601621PA (pl) |
| SI (1) | SI2726092T1 (pl) |
| SM (1) | SMT201900520T1 (pl) |
| UA (2) | UA124083C2 (pl) |
| WO (1) | WO2013003641A2 (pl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3628327A1 (en) | 2011-06-24 | 2020-04-01 | The Regents of the University of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| CN110551223A (zh) | 2011-06-28 | 2019-12-10 | 英伊布里克斯有限合伙公司 | 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法 |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| AU2012275295B2 (en) * | 2011-06-28 | 2016-11-10 | Inhibrx, Lp | WAP domain fusion polypeptides and methods of use thereof |
| AU2013202648B2 (en) * | 2012-01-10 | 2016-05-19 | Konkuk University | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| WO2013156054A1 (en) * | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| US20150210753A1 (en) | 2012-07-26 | 2015-07-30 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| KR101509020B1 (ko) * | 2013-05-22 | 2015-04-14 | (주)입디 | 알파 1 안티트립신 융합 분자에 대한 조성물, 방법 및 용도 |
| WO2015191892A2 (en) | 2014-06-11 | 2015-12-17 | Beth Israel Deaconess Medical Center, Inc. | α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES |
| EP3042201B1 (en) | 2014-07-23 | 2020-03-04 | Inova Diagnostics, Inc. | Compositions and methods for the diagnosis of rheumatoid arthritis |
| SG11201703390SA (en) * | 2014-10-27 | 2017-05-30 | Inhibrx Lp | Serpin fusion polypeptides and methods of use thereof |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| US11422719B2 (en) | 2016-09-15 | 2022-08-23 | Pure Storage, Inc. | Distributed file deletion and truncation |
| WO2018183705A1 (en) | 2017-03-29 | 2018-10-04 | Cornell University | Oxidation-resistant aat gene therapy |
| ES2998765T3 (en) * | 2017-07-27 | 2025-02-21 | Univ Michigan Regents | Plasminogen activator inhibitor-1 (pai-1) inhibitor and method of use |
| CN109705211B (zh) | 2017-10-26 | 2020-08-18 | 苏州复融生物技术有限公司 | 一种IgG1 Fc单体及其应用 |
| PT3716998T (pt) | 2017-12-01 | 2024-04-09 | Csl Behring Llc | A1at para reduzir risco de início de doença do enxerto contra hospedeiro aguda após transplante de células hematopoiéticas |
| CA3117961A1 (en) * | 2018-10-29 | 2020-05-07 | Spin Therapeutics, Llc | Compositions and methods for alpha-1-antitrypsin disorders |
| EP4582442A3 (en) | 2019-06-24 | 2025-10-29 | Universität Stuttgart | Tnfr2 agonists with improved stability |
| CA3145702A1 (en) * | 2019-08-01 | 2021-02-04 | Philip A. Pemberton | Oxidation-resistant serpins |
| CN114867865A (zh) * | 2019-11-21 | 2022-08-05 | 密执安大学评议会 | 中性粒细胞弹性蛋白酶活性的多肽抑制剂及其用途 |
| CN110964094B (zh) * | 2019-12-20 | 2021-11-02 | 华中科技大学 | 人源白细胞蛋白酶抑制因子及其重组制备与应用 |
| CN112341538A (zh) * | 2020-10-27 | 2021-02-09 | 苏州复融生物技术有限公司 | 一种Fc单体多肽及其应用 |
| JP2024505203A (ja) * | 2021-01-26 | 2024-02-05 | ナショナル リサーチ カウンシル オブ カナダ | Ａｃｅ２受容体エクトドメイン融合分子及びその使用 |
| GB202102258D0 (en) | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
| US20250049898A1 (en) * | 2021-12-22 | 2025-02-13 | The Regents Of The University Of California | Compositions and methods for wound healing |
| US20230364208A1 (en) | 2022-05-16 | 2023-11-16 | Inhibrx, Inc. | Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject |
| CN115466323B (zh) * | 2022-09-13 | 2025-07-01 | 宁波博睿瀚达生物科技有限公司 | 一种分离分泌性白细胞蛋白酶抑制因子的方法 |
| EP4483951A1 (en) * | 2023-06-30 | 2025-01-01 | Université de Liège | Single-domain antibody for inhibition of neutrophil elastase activity |
| WO2025083294A2 (en) | 2024-02-29 | 2025-04-24 | Ageronix SA | Aat-fc fusion protein |
| WO2025219443A1 (en) | 2024-04-19 | 2025-10-23 | Uniqure Biopharma B.V. | Nucleic acid for a1at regulation |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7253264B1 (en) * | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| EP0628639B1 (en) | 1991-04-25 | 1999-06-23 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| US5734014A (en) | 1992-08-11 | 1998-03-31 | Tsumura & Co. | Elafin derivative |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| TW575567B (en) * | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU3609300A (en) * | 1999-03-01 | 2000-09-21 | Human Genome Sciences, Inc. | Human serpin proteins |
| US6849605B1 (en) * | 1999-03-05 | 2005-02-01 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
| WO2001001748A2 (en) | 1999-07-02 | 2001-01-11 | Genentech, Inc. | Peptide compounds that bind her2 |
| WO2001040249A1 (en) | 1999-12-01 | 2001-06-07 | Human Genome Sciences, Inc. | Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| FR2814957B1 (fr) | 2000-10-06 | 2002-12-20 | Aventis Pasteur | Composition vaccinale et procede de stabilisation |
| AU2002212606A1 (en) * | 2000-11-08 | 2002-05-21 | Prometic Biosciences Inc | Method for the treatment of inflammation |
| BR0116024A (pt) | 2000-12-07 | 2005-12-13 | Lilly Co Eli | Proteìna de fusão heteróloga e uso da mesma |
| PT1355919E (pt) * | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7247704B2 (en) * | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
| EP1366175B1 (en) * | 2000-12-18 | 2008-01-23 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
| US7211395B2 (en) * | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| US6797493B2 (en) | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1415664A1 (en) * | 2002-10-30 | 2004-05-06 | Switch Biotech Aktiengesellschaft | Use of alpha 1-antichymotrypsin in combination with alpha-1-antitrypsin for treating/preventing diabetes associated or poorly healing arterial wounds |
| US7427595B1 (en) | 2002-12-12 | 2008-09-23 | Cornell Research Foundation, Inc. | Use of proepithelin to promote wound repair and reduce inflammation |
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US20070253966A1 (en) | 2003-06-12 | 2007-11-01 | Eli Lilly And Company | Fusion Proteins |
| US7850970B2 (en) | 2003-08-26 | 2010-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| ATE555133T1 (de) * | 2003-11-13 | 2012-05-15 | Hanmi Holdings Co Ltd | Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| CA2559062A1 (en) * | 2004-03-09 | 2005-09-22 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| SI1751184T1 (sl) | 2004-05-13 | 2010-01-29 | Lilly Co Eli | Fgf-21 fuzijski proteini |
| JP5188804B2 (ja) | 2004-08-03 | 2013-04-24 | トランステック ファーマ，インコーポレイティド | Ｒａｇｅ融合タンパク質及びその使用方法 |
| BRPI0514259A (pt) | 2004-08-11 | 2008-06-03 | Trubion Pharmaceuticals Inc | proteìna de fusão de domìnio de ligação |
| US7399746B2 (en) | 2004-10-06 | 2008-07-15 | Mcgill University | Agents for wound healing |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| EP3479844B1 (en) * | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| CA2609262A1 (en) | 2005-06-03 | 2006-12-07 | Mochida Pharmaceutical Co., Ltd. | Anti-cd14 antibody fusion protein |
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| MX2008002101A (es) | 2005-08-12 | 2008-04-19 | Schering Corp | Fusiones de la proteina-1 quimiotactica de monocito. |
| KR20190006086A (ko) * | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| WO2007117440A2 (en) | 2006-03-30 | 2007-10-18 | Research Foundation Of City University Of New York | Stimulation of neuron regeneration by secretory leukocyte protease inhibitor |
| GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| EA017733B1 (ru) * | 2006-08-28 | 2013-02-28 | Арес Трейдинг С.А. | СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ |
| US20110020269A1 (en) | 2007-05-08 | 2011-01-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
| CN105131127B (zh) * | 2007-05-30 | 2018-09-07 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| CA2688433A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
| WO2009045508A1 (en) * | 2007-10-02 | 2009-04-09 | Research Foundation Of City University Of New York | Novel protein transduction domains derived from secretory leukocyte protease inhibitor |
| AR064713A1 (es) | 2007-12-28 | 2009-04-22 | Consejo Nac Invest Cient Tec | Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos |
| EP2307456B1 (en) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| UA101670C2 (ru) * | 2008-07-23 | 2013-04-25 | Ханми Сайенс Ко., Лтд. | Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца |
| CN102171343B (zh) | 2008-08-04 | 2017-07-14 | 戊瑞治疗有限公司 | Fgfr细胞外结构域酸性区突变蛋白 |
| EP2376109B1 (en) | 2008-12-19 | 2019-01-23 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| NZ595461A (en) | 2009-04-10 | 2013-01-25 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| WO2010123290A2 (ko) * | 2009-04-22 | 2010-10-28 | (주)알테오젠 | 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법 |
| SE533763C2 (sv) | 2009-05-04 | 2010-12-28 | Lars Hammar | Upphängningsanordning |
| CA2767545C (en) | 2009-07-08 | 2019-09-17 | The Curators Of The University Of Missouri | High oleic acid soybean with mutant fad2-1a and fad2-1b genes and method of producing the same |
| AU2010319327B2 (en) | 2009-11-13 | 2015-08-13 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| GB201003559D0 (en) | 2010-03-03 | 2010-04-21 | Proteo Biotech Ag | Novel use of elafin |
| WO2012003290A2 (en) | 2010-06-30 | 2012-01-05 | University Of Maryland, Baltimore | Dental composites comprising nanoparticles of amorphous calcium phosphate |
| CA2822366A1 (en) | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| SG10201602394QA (en) | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| EP3628327A1 (en) * | 2011-06-24 | 2020-04-01 | The Regents of the University of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| EP2537864B1 (en) | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| CN110551223A (zh) | 2011-06-28 | 2019-12-10 | 英伊布里克斯有限合伙公司 | 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法 |
| AU2012275295B2 (en) | 2011-06-28 | 2016-11-10 | Inhibrx, Lp | WAP domain fusion polypeptides and methods of use thereof |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| CN113244374A (zh) * | 2011-07-01 | 2021-08-13 | 生物基因Ma公司 | 无精氨酸的tnfr:fc-融合多肽组合物及使用方法 |
| AU2013202648B2 (en) | 2012-01-10 | 2016-05-19 | Konkuk University | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| TW201402611A (zh) | 2012-06-21 | 2014-01-16 | Univ Indiana Res & Tech Corp | 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物 |
| WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| CN104508132B (zh) | 2012-08-02 | 2017-09-15 | 弗·哈夫曼-拉罗切有限公司 | 用于产生作为与惰性免疫球蛋白Fc区Fc融合的可溶FcR的方法及其用途 |
| JP6345688B2 (ja) | 2012-12-05 | 2018-06-20 | ソラ・バイオサイエンシズ・エルエルシー | タンパク質発現増強ポリペプチド |
| CN203917563U (zh) | 2014-03-27 | 2014-11-05 | 陈广煌 | 一种切角模具 |
| WO2015191892A2 (en) * | 2014-06-11 | 2015-12-17 | Beth Israel Deaconess Medical Center, Inc. | α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES |
-
2012
- 2012-06-28 CN CN201910871347.6A patent/CN110551223A/zh active Pending
- 2012-06-28 RU RU2019121797A patent/RU2727452C1/ru active
- 2012-06-28 PL PL12804863T patent/PL2726092T3/pl unknown
- 2012-06-28 CN CN201910132137.5A patent/CN110066340B/zh active Active
- 2012-06-28 IL IL312872A patent/IL312872A/en unknown
- 2012-06-28 UA UAA201400709A patent/UA124083C2/uk unknown
- 2012-06-28 ES ES12804863T patent/ES2746052T3/es active Active
- 2012-06-28 RU RU2017145308A patent/RU2698655C2/ru active
- 2012-06-28 RU RU2014102583A patent/RU2642310C2/ru active
- 2012-06-28 KR KR1020257001261A patent/KR20250012200A/ko active Pending
- 2012-06-28 HR HRP20191652 patent/HRP20191652T1/hr unknown
- 2012-06-28 MX MX2018006710A patent/MX381183B/es unknown
- 2012-06-28 CA CA2839619A patent/CA2839619C/en active Active
- 2012-06-28 KR KR1020207005907A patent/KR102231139B1/ko active Active
- 2012-06-28 NZ NZ744257A patent/NZ744257A/en unknown
- 2012-06-28 KR KR1020147002346A patent/KR102084944B1/ko active Active
- 2012-06-28 KR KR1020237024532A patent/KR102756547B1/ko active Active
- 2012-06-28 KR KR1020217007901A patent/KR20210032558A/ko not_active Ceased
- 2012-06-28 CN CN201280041956.5A patent/CN103917563A/zh active Pending
- 2012-06-28 AU AU2012275287A patent/AU2012275287B2/en active Active
- 2012-06-28 WO PCT/US2012/044730 patent/WO2013003641A2/en not_active Ceased
- 2012-06-28 IN IN2441MUN2013 patent/IN2013MN02441A/en unknown
- 2012-06-28 EP EP12804863.4A patent/EP2726092B1/en active Active
- 2012-06-28 DK DK12804863.4T patent/DK2726092T3/da active
- 2012-06-28 CA CA3132298A patent/CA3132298A1/en active Pending
- 2012-06-28 SG SG10201601621PA patent/SG10201601621PA/en unknown
- 2012-06-28 BR BR112013033799A patent/BR112013033799A2/pt not_active Application Discontinuation
- 2012-06-28 JP JP2014519049A patent/JP2014523900A/ja active Pending
- 2012-06-28 IL IL276534A patent/IL276534B2/en unknown
- 2012-06-28 KR KR1020217043197A patent/KR20220003656A/ko not_active Ceased
- 2012-06-28 EP EP19181040.7A patent/EP3569243A1/en active Pending
- 2012-06-28 SM SM20190520T patent/SMT201900520T1/it unknown
- 2012-06-28 ME MEP-2019-253A patent/ME03473B/me unknown
- 2012-06-28 SI SI201231670T patent/SI2726092T1/sl unknown
- 2012-06-28 LT LTEP12804863.4T patent/LT2726092T/lt unknown
- 2012-06-28 US US13/536,976 patent/US8980266B2/en active Active
- 2012-06-28 PT PT128048634T patent/PT2726092T/pt unknown
- 2012-06-28 SG SG10201811256QA patent/SG10201811256QA/en unknown
- 2012-06-28 UA UAA201902302A patent/UA130601C2/uk unknown
- 2012-06-28 RS RSP20191200 patent/RS59368B1/sr unknown
- 2012-06-28 HU HUE12804863A patent/HUE046156T2/hu unknown
- 2012-06-28 MX MX2013015323A patent/MX356517B/es active IP Right Grant
-
2013
- 2013-08-19 US US13/969,959 patent/US9920109B2/en active Active
- 2013-12-26 IL IL230209A patent/IL230209B/en active IP Right Grant
-
2015
- 2015-02-06 US US14/616,363 patent/US10730929B2/en active Active
-
2017
- 2017-07-07 JP JP2017134043A patent/JP6674604B2/ja active Active
- 2017-12-21 AU AU2017279724A patent/AU2017279724B2/en active Active
-
2018
- 2018-01-19 US US15/875,010 patent/US10723785B2/en active Active
-
2019
- 2019-04-24 US US16/393,619 patent/US20200102371A1/en not_active Abandoned
- 2019-04-24 AU AU2019202904A patent/AU2019202904B2/en active Active
- 2019-07-11 RU RU2019121798A patent/RU2728861C1/ru active
- 2019-09-18 CY CY20191100993T patent/CY1122195T1/el unknown
-
2020
- 2020-02-06 JP JP2020018783A patent/JP2020078325A/ja active Pending
- 2020-06-22 US US16/908,271 patent/US11827691B2/en active Active
- 2020-10-08 US US17/066,410 patent/US11965017B2/en active Active
-
2021
- 2021-04-07 AU AU2021202131A patent/AU2021202131B2/en active Active
-
2022
- 2022-04-21 JP JP2022069976A patent/JP2022109968A/ja active Pending
-
2024
- 2024-03-13 US US18/604,420 patent/US20250011394A1/en active Pending
- 2024-07-09 JP JP2024110442A patent/JP2024138397A/ja active Pending
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20200424 |